foxo4 dri cancer foxo4-dri peptide senolytic human trial inhibitors targeting FOXO4-p53 interactions and inducing senescent cell-specific apoptosis FOXO4-DRI JCI Insight - Targeting senescence-like

Your provider monitors your response throughout the protocol and will adjust dosing or schedule if needed

Stimulates red blood cell production in bone marrow

Wolverine BPC-157 | TB-500 (Spray) Category Regenerative Research CAS Number N/A Form Factor Nasal Spray Blend Components BPC-157 60 mg CAS: 137525-51-0 TB-500 CAS: 77591-33-4 BPC-157 CAS 137525-51-0 Formula C 62 H 98 N 16 O 22 Molar Mass 1419.5347 g/mol TB-500 CAS 77591-33-4 Formula C 212 H 350 N 56 O 78 S Molar Mass 4963.4421 g/mol This intranasal research formulation combines BPC-157 and TB-500 for the experimental characterization of mucosal transport and systemic biodistribution

Triple-hormone-receptor agonist retatrutide for obesity-A phase 2 trial